|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAP3K9 |
Gene summary for MAP3K9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAP3K9 | Gene ID | 4293 |
| Gene name | mitogen-activated protein kinase kinase kinase 9 | |
| Gene Alias | MEKK9 | |
| Cytomap | 14q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P80192 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4293 | MAP3K9 | HCC1_Meng | Human | Liver | HCC | 1.65e-15 | -2.14e-02 | 0.0246 |
| 4293 | MAP3K9 | HCC1 | Human | Liver | HCC | 1.60e-09 | 2.66e+00 | 0.5336 |
| 4293 | MAP3K9 | HCC2 | Human | Liver | HCC | 4.95e-26 | 3.28e+00 | 0.5341 |
| 4293 | MAP3K9 | HCC5 | Human | Liver | HCC | 1.15e-19 | 2.11e+00 | 0.4932 |
| 4293 | MAP3K9 | RNA-P17T-P17T-2 | Human | Lung | IAC | 2.63e-05 | 6.15e-01 | 0.3371 |
| 4293 | MAP3K9 | RNA-P17T-P17T-4 | Human | Lung | IAC | 1.81e-07 | 6.12e-01 | 0.343 |
| 4293 | MAP3K9 | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.88e-05 | 7.17e-01 | 0.3385 |
| 4293 | MAP3K9 | RNA-P17T-P17T-8 | Human | Lung | IAC | 2.60e-03 | 5.04e-01 | 0.3329 |
| 4293 | MAP3K9 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.38e-03 | 2.18e-01 | -0.0166 |
| 4293 | MAP3K9 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 2.80e-05 | 2.60e-01 | -0.0132 |
| 4293 | MAP3K9 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 6.18e-07 | 2.59e-01 | -0.013 |
| 4293 | MAP3K9 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 7.83e-10 | 3.75e-01 | -0.0121 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00467775 | Liver | HCC | protein autophosphorylation | 123/7958 | 227/18723 | 2.40e-04 | 1.80e-03 | 123 |
| GO:00467776 | Lung | IAC | protein autophosphorylation | 51/2061 | 227/18723 | 4.85e-07 | 3.10e-05 | 51 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa040108 | Lung | IAC | MAPK signaling pathway | 62/1053 | 302/8465 | 3.54e-05 | 6.38e-04 | 4.24e-04 | 62 |
| hsa0401011 | Lung | IAC | MAPK signaling pathway | 62/1053 | 302/8465 | 3.54e-05 | 6.38e-04 | 4.24e-04 | 62 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAP3K9 | SNV | Missense_Mutation | novel | c.3103G>T | p.Ala1035Ser | p.A1035S | P80192 | protein_coding | tolerated(0.14) | probably_damaging(0.996) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | |
| MAP3K9 | SNV | Missense_Mutation | c.2917C>G | p.Pro973Ala | p.P973A | P80192 | protein_coding | deleterious(0) | possibly_damaging(0.793) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | |
| MAP3K9 | SNV | Missense_Mutation | c.496G>A | p.Asp166Asn | p.D166N | P80192 | protein_coding | deleterious(0.02) | benign(0.022) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| MAP3K9 | SNV | Missense_Mutation | c.2853G>C | p.Leu951Phe | p.L951F | P80192 | protein_coding | tolerated(0.39) | benign(0.074) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MAP3K9 | SNV | Missense_Mutation | c.1644N>A | p.Ser548Arg | p.S548R | P80192 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MAP3K9 | insertion | Nonsense_Mutation | novel | c.2625_2626insGGCACAGCCCTTTCTCAGGGTTGGACCCCCTGAGATCCAGCCCT | p.Met876GlyfsTer11 | p.M876Gfs*11 | P80192 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| MAP3K9 | SNV | Missense_Mutation | rs747893572 | c.3050N>A | p.Arg1017Gln | p.R1017Q | P80192 | protein_coding | deleterious(0.05) | probably_damaging(0.947) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MAP3K9 | SNV | Missense_Mutation | c.1396N>T | p.Arg466Trp | p.R466W | P80192 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MAP3K9 | SNV | Missense_Mutation | c.1237G>C | p.Glu413Gln | p.E413Q | P80192 | protein_coding | tolerated(0.32) | benign(0.108) | TCGA-DG-A2KL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| MAP3K9 | SNV | Missense_Mutation | c.775N>A | p.Glu259Lys | p.E259K | P80192 | protein_coding | deleterious(0) | possibly_damaging(0.729) | TCGA-DS-A0VK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4293 | MAP3K9 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, ENZYME, SERINE THREONINE KINASE | inhibitor | CHEMBL290352 | CEP-1347 | |
| 4293 | MAP3K9 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, ENZYME, SERINE THREONINE KINASE | inhibitor | 310264738 | CERDULATINIB | |
| 4293 | MAP3K9 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, ENZYME, SERINE THREONINE KINASE | CEP1347 | |||
| 4293 | MAP3K9 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, ENZYME, SERINE THREONINE KINASE | inhibitor | 249565853 | CEP-1347 | |
| 4293 | MAP3K9 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, ENZYME, SERINE THREONINE KINASE | inhibitor | 249565786 | ||
| 4293 | MAP3K9 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, ENZYME, SERINE THREONINE KINASE | inhibitor | 249565579 | APITOLISIB | |
| 4293 | MAP3K9 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, ENZYME, SERINE THREONINE KINASE | inhibitor | 328083457 | ||
| 4293 | MAP3K9 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, ENZYME, SERINE THREONINE KINASE | inhibitor | 249565817 | ||
| 4293 | MAP3K9 | DRUGGABLE GENOME, TRANSCRIPTION FACTOR, KINASE, ENZYME, SERINE THREONINE KINASE | inhibitor | 249565750 | PRT-2607 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |